310 related articles for article (PubMed ID: 17324131)
1. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
Feagan BG; Reinisch W; Rutgeerts P; Sandborn WJ; Yan S; Eisenberg D; Bala M; Johanns J; Olson A; Hanauer SB
Am J Gastroenterol; 2007 Apr; 102(4):794-802. PubMed ID: 17324131
[TBL] [Abstract][Full Text] [Related]
2. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
3. The effects of infliximab maintenance therapy on health-related quality of life.
Feagan BG; Yan S; Bala M; Bao W; Lichtenstein GR
Am J Gastroenterol; 2003 Oct; 98(10):2232-8. PubMed ID: 14572573
[TBL] [Abstract][Full Text] [Related]
4. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
5. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.
Feagan BG; Sandborn WJ; Hass S; Niecko T; White J
Am J Gastroenterol; 2007 Dec; 102(12):2737-46. PubMed ID: 18042106
[TBL] [Abstract][Full Text] [Related]
7. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
8. Infliximab in the treatment of steroid-dependent ulcerative colitis.
Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236
[TBL] [Abstract][Full Text] [Related]
9. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis.
Irvine EJ; Yeh CH; Ramsey D; Stirling AL; Higgins PD
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1278-86. PubMed ID: 18808446
[TBL] [Abstract][Full Text] [Related]
10. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
[TBL] [Abstract][Full Text] [Related]
11. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
[TBL] [Abstract][Full Text] [Related]
12. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
Reich K; Nestle FO; Wu Y; Bala M; Eisenberg D; Guzzo C; Li S; Dooley LT; Griffiths CE
Eur J Dermatol; 2007; 17(5):381-6. PubMed ID: 17673380
[TBL] [Abstract][Full Text] [Related]
13. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
[TBL] [Abstract][Full Text] [Related]
14. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.
Reinisch W; Sandborn WJ; Bala M; Yan S; Feagan BG; Rutgeerts P; Radford-Smith G; Xu S; Eisenberg D; Olson A; Colombel JF
Inflamm Bowel Dis; 2007 Sep; 13(9):1135-40. PubMed ID: 17476675
[TBL] [Abstract][Full Text] [Related]
15. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England.
Russo EA; Harris AW; Campbell S; Lindsay J; Hart A; Arebi N; Milestone A; Tsai HH; Walters J; Carpani M; Westaby D; Thillainayagam A; Bansi D; Ghosh S
Aliment Pharmacol Ther; 2009 Feb; 29(3):308-14. PubMed ID: 19035973
[TBL] [Abstract][Full Text] [Related]
16. Impact of persistence with infliximab on hospitalizations in ulcerative colitis.
Carter CT; Leher H; Smith P; Smith DB; Waters HC
Am J Manag Care; 2011 Jun; 17(6):385-92. PubMed ID: 21756009
[TBL] [Abstract][Full Text] [Related]
17. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
[TBL] [Abstract][Full Text] [Related]
18. Effects of a comprehensive lifestyle modification program on quality-of-life in patients with ulcerative colitis: a twelve-month follow-up.
Langhorst J; Mueller T; Luedtke R; Franken U; Paul A; Michalsen A; Schedlowski M; Dobos GJ; Elsenbruch S
Scand J Gastroenterol; 2007 Jun; 42(6):734-45. PubMed ID: 17505996
[TBL] [Abstract][Full Text] [Related]
19. Assessment of health-related quality of life after surgical treatment of focal symptomatic spinal stenosis compared with osteoarthritis of the hip or knee.
Rampersaud YR; Ravi B; Lewis SJ; Stas V; Barron R; Davey R; Mahomed N
Spine J; 2008; 8(2):296-304. PubMed ID: 17669690
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
